Eyes on Systems Pharmacology – Development of a Disease-Modifying Therapy for Retinal Degenerations

Description of the granted funding

Retinal degenerative diseases are blinding conditions that generally lack preventive therapies. Particularly Age-related Macular Degeneration is a major healthcare burden. A treatment that would slow degeneration regardless of the underlying pathology could lead to satisfactory resolution fastest, especially if based on clinical drugs approved for use in other indications. I have spent several years in the USA working on a combinational drug treatment concept that capitalizes on drug repurposing. We have shown that the treatment is effective against retinal degeneration in many disease models. My intent is to continue this research in Finland. Specifically, I start working towards intraocularly administered therapy to minimize drug side effects. My aim is to develop the first clinical treatment to slow progression of retinal degeneration. The use of multiple cooperating drugs, repurposing and local administration in a single regimen would become an unprecedented medical advancement.
Show more

Starting year

2021

End year

2026

Granted funding

Henri Leinonen Orcid -palvelun logo
447 650 €

Related funding decisions

361972
Research costs of Academy Research Fellows(2024)
200 000 €
346295
Research costs of Academy Research Fellows(2021)
300 000 €

Funder

Research Council of Finland

Funding instrument

Academy research fellows

Other information

Funding decision number

339691

Fields of science

Pharmacy

Research fields

Farmasia

Identified topics

eyes, eye diseases